publication date: Mar. 27, 2015

FDA’s Richard Pazdur Named by Fortune As one of 50 “World’s Greatest Leaders”


RICHARD PAZDUR was chosen by Fortune magazine as one of 50 of the “world’s greatest leaders.

“Rarely does one hear anybody celebrate the FDA,” Pazdur’s profile reads. “But lately the agency’s gatekeeper for cancer drugs is getting nearly universal praise for his effort to speed promising medications to market. In 2014 the FDA approved the greatest number of novel drugs in almost 20 years. Under Pazdur’s leadership, says Len Lichtenfeld of the American Cancer Society, ‘the FDA has been more responsive to the needs of cancer patients.’”

Pazdur is the director of the FDA Office of Hematology and Oncology Products. The full list of the 2015 leaders is available here.


JACK GAULDIE was named vice president of research of the Research Institute of St. Joseph’s Healthcare Hamilton.

Gauldie is a distinguished university professor of pathology and molecular medicine at McMaster University. He is also director of the Institute for Molecular Medicine and Health. St. Joesph’s is the university’s academic hospital partner.

His primary area of focus has been gene therapeutics involving molecular manipulation for the treatment of diseases including cancer, arthritis and chronic lung diseases.

Gauldie previously served on advisory boards for the Canadian Institutes for Health Research, and is currently chair of the advisory board of the Ontario Research Fund.

He has received awards from the Canadian Medical Association, the Canadian Society of Clinical Chemists, and the Canadian Society for Immunology.


ELIZABETH JAFFEE was awarded the 20th annual AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research … Continue reading 41-12 FDA’s Richard Pazdur Named by Fortune As one of 50 “World’s Greatest Leaders”

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.